<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cervical adenocarcinoma in situ</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cervical adenocarcinoma in situ</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cervical adenocarcinoma in situ</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marcela G del Carmen, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John O Schorge, MD, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H181231650"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adenocarcinoma in situ (AIS) of the cervix is a premalignant precursor to cervical adenocarcinoma. The usual interval between clinically detectable AIS and early invasion appears to be at least five years, suggesting ample opportunity for screening and intervention [<a href="#rid1">1,2</a>]. Appropriate management can prevent the occurrence of invasive disease in many cases [<a href="#rid3">3</a>]. </p><p>The diagnosis and management of AIS are reviewed here. Related topics are discussed separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Glandular cells on cervical cytology (see  <a class="medical medical_review" href="/d/html/3229.html" rel="external">"Cervical cytology: Evaluation of atypical and malignant glandular cells"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invasive adenocarcinoma of the cervix (see  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a>)</p><p></p><p class="headingAnchor" id="H11311344"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>AIS is much less common than its squamous counterpart, cervical intraepithelial neoplasia (CIN) grade 3 (previously called severe dysplasia or carcinoma in situ). In a multistate surveillance study in the United States from 2008 to 2015, 470 AIS cases were documented compared with 6587 CIN 3 cases [<a href="#rid4">4</a>]. The median age of patients with AIS was older than those with CIN 3: 35 versus 31 years. White patients accounted for 69 percent of AIS cases versus 53 percent of CIN 3 cases. In contrast to previous data reporting an increase in AIS and adenocarcinoma incidence rates in recent decades [<a href="#rid5">5</a>], this study reported AIS decreased significantly in the 21 to 24 year age group, but not in any of the older age groups, and suggested that the decline was due to increasing use of human papillomavirus vaccination. </p><p class="headingAnchor" id="H2371091731"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The risk factors for AIS are the same as for invasive cervical adenocarcinoma, most notably human papillomavirus infection, particularly with subtypes 16 or 18 [<a href="#rid6">6,7</a>]. Risk factors for cervical adenocarcinoma are discussed in detail separately. (See <a class="local">'Human papillomavirus'</a> below and  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma", section on 'Epidemiology and risk factors'</a>.)</p><p class="headingAnchor" id="H186341517"><span class="h1">CLINICAL FINDINGS</span></p><p class="headingAnchor" id="H181231664"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>AIS of the cervix is typically detected as a result of cytologic cervical cancer screening. It is nearly always asymptomatic and generally not visible on physical (speculum) examination.</p><p>Rarely, patients with AIS present with vaginal bleeding, which may be postcoital [<a href="#rid8">8,9</a>]. Speculum examination may reveal that the cervix is the source of vaginal bleeding and thus prompt evaluation with cervical cytology. </p><p class="headingAnchor" id="H852913"><span class="h2">Cervical cytology</span><span class="headingEndMark"> — </span>Among patients with atypical glandular cells (AGC) on cervical cytology, 3 to 4 percent are subsequently diagnosed with AIS and 1 to 2 percent with adenocarcinoma [<a href="#rid10">10,11</a>]. Among patients diagnosed with AIS, 55 percent have a coexisting squamous lesion [<a href="#rid12">12-14</a>].</p><p>Looked at in another way, in patients who go on to receive a diagnosis of AIS, cervical cytology revealed glandular abnormalities (AGC, AIS, or adenocarcinoma) in 50 to 69 percent of patients, squamous abnormalities in 26 to 31 percent (mostly high-grade squamous intraepithelial lesions), glandular and squamous abnormalities in 15 percent, and no abnormalities in 4 percent [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/d/html/3229.html" rel="external">"Cervical cytology: Evaluation of atypical and malignant glandular cells", section on 'Risk of premalignant or malignant disease'</a>.)</p><p class="headingAnchor" id="H2924975601"><span class="h2">Human papillomavirus</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) 16 was detected in 57 percent of patients with AIS and HPV 18 was detected in 38 percent in a population-based surveillance study of patients with AIS or cervical intraepithelial neoplasia (CIN) grade 3 conducted from 2008 to 2015 [<a href="#rid4">4</a>]. By comparison, the rates of HPV 16 and 18 in patients with CIN 3 were 58 and 5 percent, respectively.</p><p class="headingAnchor" id="H4047003164"><span class="h2">Colposcopy</span><span class="headingEndMark"> — </span>AIS has similar colposcopic findings as high-grade cervical intraepithelial lesions, but the abnormalities are more likely to involve the columnar epithelium, while CIN lesions are almost always at the squamocolumnar junction. (See  <a class="medical medical_review" href="/d/html/3260.html" rel="external">"Colposcopy", section on 'Findings'</a>.)</p><p class="headingAnchor" id="H96992990"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>AIS of the uterine cervix is a microscopic histologic diagnosis based on tissue initially obtained from colposcopic-directed cervical biopsy and/or endocervical curettage (ECC) and confirmed by a diagnostic excisional procedure. (See <a class="local">'Diagnostic excisional procedure'</a> below.) </p><p>The diagnostic evaluation leading to cervical biopsy/ECC is guided by the findings on cervical cytology.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3229.html" rel="external">"Cervical cytology: Evaluation of atypical and malignant glandular cells"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a>.)</p><p></p><p class="headingAnchor" id="H156198023"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>The normal glandular architecture of the endocervical glands may be preserved in AIS, but the glands are lined by atypical columnar epithelial cells  (<a class="graphic graphic_picture graphicRef52908" href="/d/graphic/52908.html" rel="external">picture 1</a>) similar to those of invasive cervical adenocarcinoma but without stromal invasion. The most common histologic subtype is endocervical [<a href="#rid17">17,18</a>].</p><p>AIS lesions usually originate at the transformation zone with contiguous extension proximally within the endocervical canal. Lesions may also be located high in the endocervical canal and involve the deeper portions of the endocervical clefts. However, the pattern of AIS lesions varies, making diagnosis of the full extent of disease difficult in some cases. Ten to 15 percent of patients have multifocal disease ("skip" lesions) with foci of AIS that are separated by at least 2 mm of normal mucosa [<a href="#rid19">19</a>]. </p><p class="headingAnchor" id="H287093711"><span class="h1">CONFIRMATION OF DIAGNOSIS AND ASSESSMENT OF EXTENT OF DISEASE</span><span class="headingEndMark"> — </span>Nonpregnant patients with cervical AIS diagnosed with colposcopic-directed biopsy or endocervical curettage (ECC) require a diagnostic excisional procedure to confirm the diagnosis (ie, exclude invasive disease) and assess the extent of disease.</p><p>AIS is rarely diagnosed during pregnancy [<a href="#rid20">20</a>]. A diagnostic excisional procedure and ECC are generally discouraged in pregnant patients but may be performed if invasive disease is suspected. Evaluation and management of preinvasive and invasive cervical cancer in pregnant patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/4805.html" rel="external">"Cervical cancer in pregnancy"</a>.)</p><p class="headingAnchor" id="H1945033927"><span class="h2">Diagnostic excisional procedure</span><span class="headingEndMark"> — </span>A diagnostic excisional procedure is performed in order to obtain an intact specimen with interpretable margins. One of several techniques can be used, including cold knife conization (CKC), loop electrosurgical excision procedure (LEEP), or laser conization (see  <a class="medical medical_review" href="/d/html/3255.html" rel="external">"Cervical intraepithelial neoplasia: Diagnostic excisional procedures"</a>). Ideally, a single surgical specimen should be obtained measuring at least 10 mm in length [<a href="#rid21">21</a>]. In patients in whom future pregnancy is not planned and the concerns about potential adverse pregnancy complications are low, this can be increased to 18 to 20 mm. These measurements are preferred, regardless of whether hysterectomy is planned.</p><p>There is no evidence that the type of diagnostic excisional procedure impacts outcomes as long as a negative margin is achieved. In our practice, we prefer CKC because:</p><p class="bulletIndent1"><span class="glyph">●</span>CKC specimens typically have a greater depth and width compared with LEEP specimens [<a href="#rid22">22-24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LEEP and laser conization specimens may have significant thermal artifact at the edges, especially when not expertly performed, which may obscure assessment of the margins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CKC specimens are designed to be excised in one piece and are easily marked at the 12 o'clock position, allowing the pathologist to report the anatomic location of a positive margin. LEEP specimens may be removed in two or more pieces, typically unoriented, so that margins are more likely to be uninterpretable by the pathologist.</p><p></p><p>In expert hands, CKC, LEEP, and laser conization are all reasonable approaches, yet CKC may have a higher likelihood of negative margins for the reasons stated above. LEEP may be selected because of clinician preference for an office procedure rather than a procedure under anesthesia in the operating room or, more commonly, because there was no preoperative suspicion of glandular disease during treatment of a high-grade squamous intraepithelial lesion [<a href="#rid15">15,25</a>]. If LEEP is performed, an additional pass with a smaller diameter loop ("top hat") should <strong>not</strong> be performed as one uninterrupted surgical specimen is preferred [<a href="#rid21">21</a>]. Patients who undergo LEEP are managed the same way as those who undergo CKC [<a href="#rid25">25</a>]. Laser conization results in a specimen of comparable size to CKC but is limited by the need for specialized training and equipment.</p><p class="headingAnchor" id="H411745254"><span class="h2">Post-diagnostic excisional procedure endocervical curettage</span><span class="headingEndMark"> — </span>Endocervical sampling above the excisional bed is preferred after completing the diagnostic excisional procedure since it does not add to operative risk and potentially provides additional reassurance (if negative) or indicates the need for another excision (if positive) [<a href="#rid21">21,26</a>]. We consider the ECC results to be part of the margin status (ie, a positive ECC is a positive margin). Data conflict regarding whether performing ECC provides additional information regarding the likelihood of residual disease beyond that provided by positive or negative margin status of the cone biopsy [<a href="#rid26">26-28</a>]. </p><p class="headingAnchor" id="H181231671"><span class="h1">APPROACH TO MANAGEMENT</span><span class="headingEndMark"> — </span>Hysterectomy is the standard treatment for AIS; the alternative is an excisional procedure followed by surveillance. The choice of approach depends on future childbearing plans and whether excisional margins and endocervical curettage (ECC) specimens are free of disease. Some patients with AIS on colposcopic-directed biopsy will not have AIS in the cone biopsy or ECC specimen: We manage them the same way as patients with AIS in the excisional specimen and negative ECC and excisional margins since a histologic diagnosis of AIS has been previously documented. </p><p>The following recommendations are consistent with guidelines from the American Society for Colposcopy and Cervical Pathology, the United States National Comprehensive Cancer Network, and the American College of Obstetricians and Gynecologists [<a href="#rid21">21,29,30</a>]. Based upon the complexity of managing AIS, referral to a gynecologic oncologist is generally preferred [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H15587586"><span class="h2">Patients with AIS who do not desire fertility preservation</span><span class="headingEndMark"> — </span>We recommend hysterectomy for patients with AIS who do not desire fertility preservation. Hysterectomy eliminates residual disease, which is likely to progress to invasive disease, although this may take five or more years [<a href="#rid1">1,2</a>]. Hysterectomy also reduces the risks of developing recurrent AIS and missing a concomitant or subsequent adenocarcinoma. Although there are rare reports of a diagnosis of cervical adenocarcinoma years after hysterectomy for treatment of AIS [<a href="#rid31">31,32</a>], these reports most likely represent adenocarcinoma that was not recognized at the time of hysterectomy, even though in both of the reported cases the hysterectomy specimen showed AIS without evidence of invasive disease with negative margins.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with excisional margins or ECC positive for AIS, an excisional procedure alone is associated with a high risk for residual/recurrent AIS or adenocarcinoma. In a meta-analysis of observational studies evaluating the predictive value of excisional margin status in patients with AIS, when the initial excisional margin was positive, the rate of residual or recurrent AIS was 19.4 and 52.8 percent, respectively, and the rate of concomitant or subsequent invasive adenocarcinoma was 5.2 percent, based on data from patients who underwent hysterectomy or repeat conization [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with excisional margins and ECC negative for AIS, we still recommend hysterectomy because the alternative, surveillance, has not been proven effective in preventing progression to invasive disease. Because of the pattern of disease distribution of AIS (multifocal, high in the endocervical canal, inside endocervical clefts), negative margins on a cone biopsy specimen or a negative ECC does not necessarily ensure that the lesion has been completely excised. This also greatly limits the ability of surveillance with cervical cytology, colposcopy, biopsy, and endocervical sampling to detect residual or recurrent disease or adenocarcinoma, so adenocarcinoma may be diagnosed at a more advanced stage, reducing survival compared with hysterectomy soon after conization. In the meta-analysis described above, when the initial excisional margin was negative, the rate of residual or recurrent AIS was 2.6 and 20.3 percent, respectively, and the rate of concomitant or subsequent invasive adenocarcinoma was 0.07 percent [<a href="#rid14">14</a>]. By comparison, the risk of morbidity from extrafascial hysterectomy is 4 to 6 percent  (<a class="graphic graphic_table graphicRef79688" href="/d/graphic/79688.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/3311.html" rel="external">"Hysterectomy: Abdominal (open) route", section on 'Complications'</a>.)</p><p></p><p class="headingAnchor" id="H3459742747"><span class="h2">Patients with AIS who desire fertility preservation</span><span class="headingEndMark"> — </span>For patients who desire fertility preservation and who have excisional margins or ECC positive for AIS, we perform a repeat diagnostic excisional procedure approximately six weeks after the first excisional procedure to allow for sufficient healing and resolution of inflammation of the cervix. If the repeat excisional margin or ECC is also positive, we recommend hysterectomy to reduce the risks of residual or recurrent disease and concomitant or subsequent invasive adenocarcinoma, as described above. Although a third excisional procedure is sometimes technically feasible, the risk of operative complications and preterm delivery in subsequent pregnancy increases with repeat procedures (see  <a class="medical medical_review" href="/d/html/3255.html" rel="external">"Cervical intraepithelial neoplasia: Diagnostic excisional procedures", section on 'Complications'</a> and  <a class="medical medical_review" href="/d/html/3210.html" rel="external">"Reproductive effects of cervical excisional and ablative procedures"</a>). If hysterectomy becomes necessary, patients of reproductive age who have not undergone concomitant oophorectomy may be candidates for in vitro fertilization using a gestational carrier. (See  <a class="medical medical_review" href="/d/html/7431.html" rel="external">"Gestational carrier pregnancy"</a>.)</p><p>If the initial or repeat excisional margin and the ECC are negative, surveillance is an acceptable option for patients who are willing to accept a higher risk of subsequent diagnosis of cervical adenocarcinoma since negative margins do not eliminate the risk of residual or recurrent AIS or concomitant or subsequent invasive adenocarcinoma, as described above [<a href="#rid14">14</a>]. (See <a class="local">'Patients with AIS who do not desire fertility preservation'</a> above.) </p><p>Patients who desire fertility preservation should be informed that excisional cervical procedures are associated with a range of adverse reproductive outcomes in subsequent pregnancies. Fertility and obstetric outcomes for patients managed conservatively for AIS are believed to be similar to those for patients who have undergone an excisional procedure for cervical intraepithelial neoplasia (see  <a class="medical medical_review" href="/d/html/3210.html" rel="external">"Reproductive effects of cervical excisional and ablative procedures"</a>). Reproductive outcomes have not been well studied specifically in patients with AIS, but in one of the largest series (n = 101 patients with AIS), 35 patients achieved a total of 49 pregnancies during a mean follow-up of 52 months [<a href="#rid22">22</a>]. There were 35 term deliveries (76 percent), 2 preterm births secondary to preterm prelabor rupture of membranes, 8 spontaneous first-trimester miscarriages, 3 elective pregnancy terminations, and 1 ectopic pregnancy.</p><p class="headingAnchor" id="H2235509183"><span class="h2">Patients with adenocarcinoma on cone biopsy</span><span class="headingEndMark"> — </span>Patients with adenocarcinoma on conization are upstaged and evaluated and treated as appropriate. (See  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a>.)</p><p class="headingAnchor" id="H3318436856"><span class="h2">Patients with concurrent squamous intraepithelial neoplasia or carcinoma</span><span class="headingEndMark"> — </span>Coexistent squamous lesions are managed as appropriate for the squamous finding. (See  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a> and  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p class="headingAnchor" id="H3010837"><span class="h1">PREPARATION AND CHOICE OF PROCEDURE FOR HYSTERECTOMY IN PATIENTS WHO CHOOSE DEFINITIVE THERAPY</span><span class="headingEndMark"> — </span>For patients with <strong>negative</strong> excisional margins, total extrafascial hysterectomy, performed either vaginally or by minimally invasive technique, is adequate treatment for AIS. If a laparoscopic approach is used, morcellation should be avoided because an intact specimen is important for evaluation of disease margins, particularly given the likelihood of skip lesions in AIS or an occult invasive adenocarcinoma that might have been missed with a diagnostic excisional procedure. (See  <a class="medical medical_review" href="/d/html/3308.html" rel="external">"Hysterectomy: Vaginal"</a> and  <a class="medical medical_review" href="/d/html/3286.html" rel="external">"Hysterectomy: Laparoscopic"</a>.)</p><p>The choice of procedure for patients with <strong>positive</strong> excisional margins is less clear. </p><p class="bulletIndent1"><span class="glyph">●</span>One of our contributors (JS) proceeds directly to definitive treatment with an extrafascial hysterectomy given the chance of a patient having more than a microscopic invasion (stage IA1: measured stromal invasion ≤3 mm in depth) is small (5.2 percent based on the data above [<a href="#rid14">14</a>]) and stage IA1 disease would also be treated with an extrafascial hysterectomy. A minimally invasive modified radical hysterectomy with sentinel lymph node mapping is an acceptable alternative to extrafascial hysterectomy in these patients [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, another of our contributors (BG) repeats the excisional procedure in order to exclude invasive disease beyond the margin. This avoids the possibility of performing only an extrafascial hysterectomy in the setting of an occult invasive cancer that should be staged and treated with a more radical surgical procedure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the second excisional margin is negative for invasive disease, she then performs an extrafascial hysterectomy six weeks later (to allow the conization bed to heal). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the second excisional margin continues to be positive for AIS, she performs a modified radical hysterectomy with concomitant lymph node dissection or sentinel lymph node mapping. The decision to perform an open procedure versus a minimally invasive approach is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3303.html" rel="external">"Radical hysterectomy"</a>.)</p><p></p><p>The American Society for Colposcopy and Cervical Pathology guideline considers a repeat excisional procedure to achieve negative margins the preferred approach, followed by definitive treatment with either a simple or modified radical hysterectomy [<a href="#rid21">21</a>].</p><p>The ovaries may be conserved. (See  <a class="medical medical_review" href="/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy"</a>.)</p><p class="headingAnchor" id="H3586087362"><span class="h1">MONITORING AFTER SURGICAL THERAPY</span></p><p class="headingAnchor" id="H1701574"><span class="h2">Monitoring post-hysterectomy</span><span class="headingEndMark"> — </span>Patients in whom adenocarcinoma is discovered in the hysterectomy specimen should be evaluated and managed as appropriate. (See  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a>.)</p><p>The optimal surveillance strategy for patients <strong>without</strong> adenocarcinoma has not been established, and clinical practice is variable. We follow the protocol advised by the American Society for Colposcopy and Cervical Pathology (ASCCP  (<a class="graphic graphic_algorithm graphicRef127911" href="/d/graphic/127911.html" rel="external">algorithm 1</a>)) and perform vaginal fornix testing for high-risk (ie, carcinogenic or cancer associated) human papillomavirus (HPV) types annually for three years after hysterectomy [<a href="#rid21">21,33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>After three consecutive negative tests, HPV-based testing is performed at 3-year intervals for at least 25 years. If the patient remains in good health, testing can continue beyond the age of 65. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If HPV is positive, cytology should be performed. If cytology is abnormal, we evaluate with vaginal colposcopy. If colposcopy and biopsy are positive for high-grade vaginal dysplasia (glandular or squamous), the patient is treated either with an ablative procedure (eg, carbon dioxide laser or ultrasonic surgical aspiration) or excision. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If vaginal cytology results are normal, but high-risk HPV testing is positive, both tests are repeated at the next surveillance visit. If the vaginal cytology remains normal and the HPV test remains positive, colposcopy is performed with biopsy and further treatment based on the findings. (See  <a class="medical medical_review" href="/d/html/3260.html" rel="external">"Colposcopy", section on 'Vaginal colposcopy'</a>.)</p><p></p><p class="headingAnchor" id="H3011642"><span class="h2">Monitoring post-excisional procedure</span><span class="headingEndMark"> — </span>There are no data to establish the optimal surveillance schedule for patients treated for AIS with a diagnostic excisional procedure alone. We follow the protocol advised by the ASCCP, the United States National Comprehensive Cancer Network, and the American College of Obstetricians and Gynecologists  (<a class="graphic graphic_algorithm graphicRef127911" href="/d/graphic/127911.html" rel="external">algorithm 1</a>) [<a href="#rid21">21,29,30,33,34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Co-testing with cervical cytology and high-risk HPV testing with endocervical curettage (ECC) every six months for three years. Colposcopy may also be performed, but it is often difficult to see the entire transformation zone and thus is unsatisfactory.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When both cervical cytology and high-risk HPV testing have been consistently negative for three years, the surveillance interval may be extended to annually for two years. If testing remains negative, HPV-based testing is performed at 3-year intervals until a hysterectomy has been performed or for at least 25 years. If the patient remains in good health, testing can continue beyond the age of 65. </p><p></p><p>If either cytology or HPV testing are abnormal during follow-up, the patient should be evaluated with colposcopy and ECC. Patients with adequate and negative colposcopy and a negative ECC may resume the surveillance protocol described above. Patients with recurrent AIS or high-grade squamous dysplasia on colposcopic-guided biopsy and/or ECC should undergo a repeat cervical excisional procedure or hysterectomy.</p><p class="headingAnchor" id="H2293246579"><span class="h3">Options after completion of childbearing</span><span class="headingEndMark"> — </span>After completion of childbearing, we suggest that patients with AIS who were treated with a diagnostic excisional procedure alone undergo hysterectomy. Hysterectomy reduces the risk of adenocarcinoma almost entirely compared with a 1 percent risk following an excisional procedure alone, as discussed above [<a href="#rid14">14</a>]. (See <a class="local">'Patients with AIS who do not desire fertility preservation'</a> above.)</p><p>No trials have compared continued surveillance versus deferred hysterectomy in this patient population, no studies have evaluated treatment decisions based on the results of interim cytology/HPV testing, and most studies of conservative management have followed patients for less than five years. Given the absence of data showing worse outcomes, continued surveillance is also a reasonable choice for patients who have had consistently normal testing, particularly for five or more years, following an excisional procedure. Patients can be informed that the largest series of patients who chose treatment of AIS with conization to preserve fertility included only 101 patients and had a follow-up period of an average of four years (range: 4 months to 12 years) [<a href="#rid22">22</a>]. There were no cases of adenocarcinoma, two of five patients who ultimately underwent hysterectomy had residual AIS in the hysterectomy specimen and had also had a positive excisional margin, but whether surveillance findings were the indication for hysterectomy was not reported. </p><p class="headingAnchor" id="H3310430980"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117738.html" rel="external">"Society guideline links: Cervical cancer screening, prevention, and management"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113940.html" rel="external">"Society guideline links: Treatment of cervical cancer"</a>.)</p><p class="headingAnchor" id="H181231713"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Adenocarcinoma in situ (AIS) of the cervix is a premalignant precursor to cervical adenocarcinoma. It is less common than its squamous counterpart, cervical intraepithelial neoplasia grade 3 (CIN 3). The median age of patients with AIS is approximately 35 years, and White patients account for most cases. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors are the same as for invasive cervical adenocarcinoma, most notably human papillomavirus (HPV) infection, particularly with subtype 16 or 18. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – AIS is nearly always asymptomatic and is not visible upon gross visual examination. It is typically detected as a result of cytologic cervical cancer screening. Either glandular or squamous cytologic abnormalities may precede the histologic diagnosis of AIS. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Cervical cytology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AIS is histologic diagnosis based on tissue initially obtained from colposcopic-directed cervical biopsy and/or endocervical curettage (ECC) and confirmed by a diagnostic excisional procedure. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The pattern of AIS lesions varies, making diagnosis of the full extent of disease difficult in some cases. Lesions usually originate at the cervical transformation zone and extend proximally within the endocervical canal. Lesions may also be located high in the endocervical canal and involve the deeper portions of the endocervical clefts. Most lesions are contiguous, but 10 to 15 percent of patients have multifocal disease ("skip" lesions). (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonpregnant patients with cervical AIS diagnosed with colposcopic-directed biopsy or ECC require a diagnostic excisional procedure to confirm the diagnosis (ie, exclude invasive disease) and assess the extent of disease. In our practice, we prefer cold knife conization (CKC) to a loop electrosurgical excision procedure since CKC better preserves the specimen's margins for interpretation. We perform ECC after completing the cone biopsy and consider the ECC results to be part of the margin status (ie, a positive ECC is a positive margin). (See <a class="local">'Confirmation of diagnosis and assessment of extent of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Outcomes of conservative management of AIS vary by excisional margin status. In patients with negative margins from the initial excisional procedure, the rates of residual AIS, recurrent AIS, and concomitant or subsequent invasive adenocarcinoma are approximately 2.6, 20, and &lt;1 percent, respectively; with positive margins, these rates are approximately 19, 53, and 5 percent, respectively. (See <a class="local">'Patients with AIS who do not desire fertility preservation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management for</strong> <strong>patients done with childbearing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>With negative margins –</strong> For patients with AIS who do not wish to preserve fertility and have negative margins on conization, we suggest total extrafascial hysterectomy, preferably performed vaginally or as a laparoscopic-assisted vaginal hysterectomy rather than surveillance (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Hysterectomy eliminates residual AIS (if present), which is likely to progress to invasive disease, and reduces the risks of developing recurrent AIS and missing a concomitant or subsequent adenocarcinoma. Surveillance is an option for those who value avoiding the potential morbidity of hysterectomy more than avoidance of an approximately 1 percent risk of cervical adenocarcinoma. (See <a class="local">'Patients with AIS who do not desire fertility preservation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>With positive margins</strong> – For patients with AIS who do not wish to preserve fertility and have positive margins on the initial diagnostic excisional procedure, the choice of procedure is less clear. Our contributors differ in their practice, with one proceeding directly to hysterectomy and another performing a repeat excisional procedure to exclude the presence of invasive disease beyond the initial margin. After the repeat excisional procedure, if margins are still positive, this contributor suggests a modified radical hysterectomy with concomitant pelvic lymph node dissection or sentinel lymph node mapping, rather than extrafascial hysterectomy, since invasive disease has not been adequately excluded (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preparation and choice of procedure for hysterectomy in patients who choose definitive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management for</strong> <strong>patients desiring fertility preservation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>With negative margins or ECC</strong> – For patients with AIS who desire fertility preservation and have a negative initial or repeat excisional margin and negative ECC, surveillance is an acceptable option if they are willing to accept a higher risk of subsequent diagnosis of cervical adenocarcinoma, as negative margins do not eliminate the risk of residual or recurrent AIS or concomitant or subsequent invasive adenocarcinoma. (See <a class="local">'Patients with AIS who desire fertility preservation'</a> above and <a class="local">'Monitoring post-excisional procedure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>With positive margins or ECC</strong> – For patients with AIS who desire fertility preservation and have excisional margins or ECC positive for AIS, we perform a repeat excisional procedure approximately six weeks after the first excisional procedure to allow for sufficient healing and resolution of inflammation of the cervix. If the repeat excisional margin or ECC is also positive, we suggest a modified radical hysterectomy with concomitant pelvic lymph node dissection or sentinel lymph node mapping rather than another excisional procedure (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The risk of operative complications and preterm delivery in subsequent pregnancy increases with repeat excisional procedures. (See <a class="local">'Patients with AIS who desire fertility preservation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>After completion of childbearing</strong> – For patients who opt for fertility preservation, we suggest hysterectomy after completion of childbearing (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Continued surveillance is a reasonable option for patients who have had consistently normal testing, particularly for five or more years, following an excisional procedure. (See <a class="local">'Monitoring post-excisional procedure'</a> above and <a class="local">'Options after completion of childbearing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postprocedure monitoring</strong> – The optimal surveillance strategy for patients with AIS treated with hysterectomy or a diagnostic excisional procedure has not been established, and clinical practice is variable. We follow the protocol advised by the American Society for Colposcopy and Cervical Pathology (ASCCP  (<a class="graphic graphic_algorithm graphicRef127911" href="/d/graphic/127911.html" rel="external">algorithm 1</a>)). (See <a class="local">'Monitoring after surgical therapy'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lee KR, Flynn CE. Early invasive adenocarcinoma of the cervix. Cancer 2000; 89:1048.</a></li><li><a class="nounderline abstract_t">Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 1999; 75:55.</a></li><li><a class="nounderline abstract_t">Dunton CJ. Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am 2008; 35:623.</a></li><li><a class="nounderline abstract_t">Cleveland AA, Gargano JW, Park IU, et al. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. Int J Cancer 2020; 146:810.</a></li><li><a class="nounderline abstract_t">Wang SS, Sherman ME, Hildesheim A, et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004; 100:1035.</a></li><li><a class="nounderline abstract_t">Dahlström LA, Ylitalo N, Sundström K, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010; 127:1923.</a></li><li><a class="nounderline abstract_t">Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006; 94:171.</a></li><li><a class="nounderline abstract_t">Terada T. Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. Arch Gynecol Obstet 2010; 281:527.</a></li><li><a class="nounderline abstract_t">Tobón H, Dave H. Adenocarcinoma in situ of the cervix. Clinicopathologic observations of 11 cases. Int J Gynecol Pathol 1988; 7:139.</a></li><li><a class="nounderline abstract_t">Geier CS, Wilson M, Creasman W. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol 2001; 184:64.</a></li><li><a class="nounderline abstract_t">Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107:701.</a></li><li><a class="nounderline abstract_t">Shin CH, Schorge JO, Lee KR, Sheets EE. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol 2000; 79:6.</a></li><li><a class="nounderline abstract_t">Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol 2002; 86:365.</a></li><li><a class="nounderline abstract_t">Salani R, Puri I, Bristow RE. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol 2009; 200:182.e1.</a></li><li><a class="nounderline abstract_t">Shin CH, Schorge JO, Lee KR, Sheets EE. Cytologic and biopsy findings leading to conization in adenocarcinoma in situ of the cervix. Obstet Gynecol 2002; 100:271.</a></li><li><a class="nounderline abstract_t">Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study. Acta Cytol 2004; 48:595.</a></li><li><a class="nounderline abstract_t">Gadducci A, Guerrieri ME, Cosio S. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. Crit Rev Oncol Hematol 2019; 135:103.</a></li><li><a class="nounderline abstract_t">Zaino RJ. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 2002; 21:314.</a></li><li><a class="nounderline abstract_t">Ostör AG, Duncan A, Quinn M, Rome R. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol 2000; 79:207.</a></li><li><a class="nounderline abstract_t">Lacour RA, Garner EI, Molpus KL, et al. Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol 2005; 192:1449.</a></li><li><a class="nounderline abstract_t">Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020; 24:102.</a></li><li><a class="nounderline abstract_t">Bull-Phelps SL, Garner EI, Walsh CS, et al. Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. Gynecol Oncol 2007; 107:316.</a></li><li><a class="nounderline abstract_t">Girardi F, Heydarfadai M, Koroschetz F, et al. Cold-knife conization versus loop excision: histopathologic and clinical results of a randomized trial. Gynecol Oncol 1994; 55:368.</a></li><li><a class="nounderline abstract_t">Mathevet P, Dargent D, Roy M, Beau G. A randomized prospective study comparing three techniques of conization: cold knife, laser, and LEEP. Gynecol Oncol 1994; 54:175.</a></li><li><a class="nounderline abstract_t">Bryson P, Stulberg R, Shepherd L, et al. Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS? Gynecol Oncol 2004; 93:465.</a></li><li><a class="nounderline abstract_t">Lea JS, Shin CH, Sheets EE, et al. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol 2002; 87:129.</a></li><li><a class="nounderline abstract_t">Denehy TR, Gregori CA, Breen JL. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol 1997; 90:1.</a></li><li><a class="nounderline abstract_t">Srisomboon J, Kietpeerakool C, Suprasert P, et al. Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy. Asian Pac J Cancer Prev 2007; 8:225.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol 2008; 112:1419.</a></li><li><a class="nounderline abstract_t">Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.</a></li><li><a class="nounderline abstract_t">Krivak TC, Retherford B, Voskuil S, et al. Recurrent invasive adenocarcinoma after hysterectomy for cervical adenocarcinoma in situ. Gynecol Oncol 2000; 77:334.</a></li><li><a class="nounderline abstract_t">Miller B, Dunn J, Dalrymple J, Krivak TC. Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ. Gynecol Oncol 2005; 99:489.</a></li><li class="breakAll">https://www.asccp.org/guidelines (Accessed on June 03, 2020).</li><li><a class="nounderline abstract_t">Partridge EE, Abu-Rustum N, Campos S, et al. Cervical cancer screening. J Natl Compr Canc Netw 2008; 6:58.</a></li></ol></div><div id="topicVersionRevision">Topic 3218 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10964335" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Early invasive adenocarcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502426" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061821" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of atypical glandular cells and adenocarcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30980692" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14983500" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473898" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prospective study of human papillomavirus and risk of cervical adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16404371" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19693522" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3294196" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adenocarcinoma in situ of the cervix. Clinicopathologic observations of 11 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174481" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical evaluation of atypical glandular cells of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507944" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical significance of atypical glandular cells on cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11006022" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Conservative management of adenocarcinoma in situ of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12217763" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19019325" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151149" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cytologic and biopsy findings leading to conization in adenocarcinoma in situ of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471249" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30819439" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352181" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11063645" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902134" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management of cervical adenocarcinoma in situ during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243307" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17689593" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7835776" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cold-knife conization versus loop excision: histopathologic and clinical results of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8063242" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A randomized prospective study comparing three techniques of conization: cold knife, laser, and LEEP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099963" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468353" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207802" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17696736" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19037054" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147902" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cervical cancer screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10785491" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Recurrent invasive adenocarcinoma after hysterectomy for cervical adenocarcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054200" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054200" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18267060" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cervical cancer screening.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
